CD38 Therapy in Relapsed/Refractory Multiple Myeloma
Sector
Biotech
Company
Emerging Biopharma
Therapeutic Area
Oncology
Treatment Modality
Antibody (CD38-Targeted)
Product Stage
Preclinical
Expertise
Scientific Communications
An emerging biotech advanced a CD38-targeted antibody toward first-in-human development for relapsed/refractory multiple myeloma. Entering a space dominated by established CD38 therapies, the challenge was to communicate the rationale for another entrant while highlighting preclinical signals of differentiation and translational relevance.
Situation
An emerging biotech advanced a CD38-targeted antibody toward first-in-human development for relapsed/refractory multiple myeloma. Entering a space dominated by established CD38 therapies, the challenge was to communicate the rationale for another entrant while highlighting preclinical signals of differentiation and translational relevance.
Situation
Approach
Our recommended approach focused on building a scientific narrative that clearly articulated the rationale for targeting CD38 in r/r MM, framed around resistance biology and unmet need. Preclinical data packages—including cytotoxicity, safety modeling, and activity in resistant disease models—should be translated into abstracts and early publications to build visibility. Advisory boards with hematology KOLs would refine positioning and stress-test Phase 1 trial design, while congress activity should center on presenting mechanism-of-action and translational findings at major hematology meetings.
Our recommended approach focused on building a scientific narrative that clearly articulated the rationale for targeting CD38 in r/r MM, framed around resistance biology and unmet need. Preclinical data packages—including cytotoxicity, safety modeling, and activity in resistant disease models—should be translated into abstracts and early publications to build visibility. Advisory boards with hematology KOLs would refine positioning and stress-test Phase 1 trial design, while congress activity should center on presenting mechanism-of-action and translational findings at major hematology meetings.
Approach
Results
By emphasizing scientific rigor, unmet patient need, and mechanistic differentiation, the company could lay a credible foundation for Phase 1 entry. Coordinated publications, KOL alignment, and early congress presence would build anticipation ahead of clinical readouts, helping the program gain visibility despite the crowded CD38 landscape.
By emphasizing scientific rigor, unmet patient need, and mechanistic differentiation, the company could lay a credible foundation for Phase 1 entry. Coordinated publications, KOL alignment, and early congress presence would build anticipation ahead of clinical readouts, helping the program gain visibility despite the crowded CD38 landscape.
Situation
An emerging biotech advanced a CD38-targeted antibody toward first-in-human development for relapsed/refractory multiple myeloma. Entering a space dominated by established CD38 therapies, the challenge was to communicate the rationale for another entrant while highlighting preclinical signals of differentiation and translational relevance.
Approach
Our recommended approach focused on building a scientific narrative that clearly articulated the rationale for targeting CD38 in r/r MM, framed around resistance biology and unmet need. Preclinical data packages—including cytotoxicity, safety modeling, and activity in resistant disease models—should be translated into abstracts and early publications to build visibility. Advisory boards with hematology KOLs would refine positioning and stress-test Phase 1 trial design, while congress activity should center on presenting mechanism-of-action and translational findings at major hematology meetings.
Results
By emphasizing scientific rigor, unmet patient need, and mechanistic differentiation, the company could lay a credible foundation for Phase 1 entry. Coordinated publications, KOL alignment, and early congress presence would build anticipation ahead of clinical readouts, helping the program gain visibility despite the crowded CD38 landscape.
*Impact studies reflect the collective experience of Biography and its partners.
Other Work
Let's Partner
Generating the
Biology Century
We help life sciences teams cut through complexity and move from biology to belief—sharper, faster, leaner.
Let's Partner
Generating the
Biology Century
We help life sciences teams cut through complexity and move from biology to belief—sharper, faster, leaner.
Let's Partner
Generating the
Biology Century
We help life sciences teams cut through complexity and move from biology to belief—sharper, faster, leaner.